- Email: [email protected]
Cumulative chapter titles keyword index, volumes 1–36
CUMULATIVE
CHAPTER TITLES KEYWORD INDEX. VOLUMES l-36
acetylcholine receptors, 30, 41 acetylcholine transporter, 28, 247 adenylate cyclase, S, 227, 233; l2, 172; 19, 293; 29, 287 adenosine, 33, 111 adenosine, neuromodulator, l8, 1; 23, 39 adjuvants, 9, 244 ADME by computer, 36,257 ADME properties, 34, 307 adrenal steroidogenesis, 2, 263 adrenergic receptor antagonists, 35, 221 I3-adrenergic blockers, IO, 51; 14, 81 t3-adrenergic receptor agonists, 33, 193 affinity labeling, 9, 222 l33-agonists, 3J, 189 AIDS, 23, 161,253; 25, 149 alcohol consumption, drugs and deterrence, 3, 246 aldose reductase, l9, 169 alkaloids, 1, 311; 3, 358; 4, 322; 5, 323; 6, 274 allergic eosinophilia; 34, 61 allergy, 29, 73 alopecia, 24, 187 Alzheimer’s Disease, 2, 229; 3, 49, 197, 247; 32, 11; 34, 21; 3, 31 aminocyclitol antibiotics, l2, 110 t3-amyloid, 2, 21 amyloid, 28, 49; 32, 11 amyloidogenesis, 26, 229 analgesics (analgetic), 1, 40; 2, 33; 3, 36; 4, 37; 5, 31; 6, 34; 7, 31; 6, 20; 9, 11; IO, 12; II, 23; l2, 20; l3, 41; l4, 31; l5, 32; I& 41; l7, 21; l8, 51; IJ, 1; 20, 21;2J,21;23,11;25,11;3J, 11;33,11 androgen action, 21, 179; 29, 225 androgen receptor modulators, 36, 169 anesthetics, 1, 30; 2, 24; 3, 28; 4, 28; 1, 39; 8, 29; IJ, 30, 31, 41 angiogenesis inhibitors, 27, 139; 32, 161 angiotensinlrenin modulators, 26, 63; 27, 59 animal engineering, 29, 33 animal healthcare, 36, 319 animal models, anxiety, l5, 51 animal models, memory and learning, l2, 30 Annual Reports in Medicinal Chemistry, 25, 333 anorexigenic agents, ‘l, 51; 2, 44; 3, 47; 5, 40; 8, 42; lJ, 200; l5, 172 antagonists, calcium, l& 257; l7, 71; l8, 79 antagonists, GABA, l3, 31; l5, 41 antagonists, narcotic, 1, 31; 8, 20; 9, 11; l& 12; lJ, 23 antagonists, non-steroidal, 1, 213; 2, 208; 3, 207; 4, 199 antagonists, steroidal, 1, 213; 2, 208; 3, 207; 4, 199 anthracycline antibiotics, 14, 288 antiaging drugs, 9, 214
351 -
352
Cumulative
Chapter
Titles
Keyword
Index,
Vol. l-36
antiallergy agents, 1, 92: 2, 83; 3, 84; 7, 89; 9, 85; Q, 80; ll, 51; 12, 70; l3, 51; 14, 51; 15, 59; II, 51; 18, 61; 19, 93; 20% 71; 2l, 73; 22, 73; 3, 69; 24, 61; 25, 61; 26, 113; 27, 109 antianginals, 1, 78; 2, 69; 3, 71; 5, 63; I, 69; 8, 63; 9, 67; l2, 39; l7, 71 anti-angiogenesis, 2, 123 antianxiety agents, 1, 1; 2, 1; 3, 1; 4, 1; 51, 1; S, 1; 1, 6; 8, 1; 9, 1; IO, 2; 11, 13; ~,10;~,21;~,22;~,22;~,31;~,11;~,11;~,11;~,1;~,11;~,11; 23,19; a,11 antiarrhythmics, 1, 85; 6, 80; 8, 63; !3, 67; 2, 39; l8, 99, 21, 95; 25, 79; 27, 89 antibacterial resistance mechanisms, 28, 141 antibacterials, 1, 118; 2, 112; 3, 105; 3, 108; 5, 87; 6, 108; l7, 107; l8, 29, 113; 23, 141; 3J 101; 3l, 121; 33, 141; 34, 169; 34, 227: 3&89 antibiotic transport, 3, 139 antibiotics, 1, 109; 2, 102; 3, 93; 4, 88; 5, 75, 156: 6> 99; 7, 99, 217; i& 104; 9, 95; IO, 109, 246; IJ, 89; IJ, 271; 12, 101, 110; l3, 103, 149; l4, 103; lfj, 106; l7,107; 18,109; 2l/ 131; 23,121; 24,101; 25,119 antibiotic producing organisms, 27, 129 antibodies, cancer therapy, 23, 151 antibodies, drug carriers and toxicity reversal, IJ, 233 antibodies, monoclonal, 16, 243 anticancer agents, mechanical-based, 25, 129 anticancer drug resistance, 23, 265 anticoagulants, 3, 81; 36, 79 anticoagulant agents, 3, 83 anticonvulsants, 1, 30; 2, 24; 3, 28; 4, 28; 1, 39, 6, 29; IO, 30; IJ, 13; l2, 10; IJ, 21;~,22;~,22;~,31;~,11;~,11;~,11;~,11;~,11;~,19;~,11 antidepressants, ‘l, 12; 2, 11; 3, 14; 3, 13; 5, 13; 6, 15; 1, 18; 6, 11; 11, 3; 2, 1; l3, 1; l4, 1; IJ, 1; I& 1; -i7, 41; l8, 41; 20, 31; 22, 21; 3, 21; 26, 23; 2, 1; 34, antidiabetics, 1, 164; 2, 176; 3, 156; 4, 164; 6, 192; 21, 219 antiepileptics, 33, 61 antifungal agents, 32, 151; 33, 173, 35, 157 antifungals, 2, 157; 3, 145; 3, 138; 5, 129; 6, 129; z, 109; 8, 116; 9, 107; IJ, 120; IJ, 101; l3, 113; l5, 139; ‘lJ, 139; IQ, 127; 22, 159; 24, 111; 25, 141; 27, 149 antiglaucoma agents, 20, 83 anti-HCV therapeutics, 34, 129 antihyperlipidemics, l5, 162; l8, 161; 24, 147 antihypertensives, 1, 59; 2, 48; 3, 53; 4, 47; 5, 49; 6, 52; 7, 59; 8, 52; 9, 57; 11, 61; IZ, 60; l3, 71; VI, 61; l5, 79; l6, 73; l7, 61; l8, 69; l9, 61; 2J, 63; 2, 63; 23, 59; 24, 51; 25, 51 antiinfective agents, 28, 119 antiinflammatory agents, 28, 109; 29, 103 antiinflammatories, non-steroidal, ?_, 224; 2, 217; 3, 215; 4, 207; 5, 225; 6, 182; 7,208;& 214;!j, 193;lO, 172; IJ, 167;E, 189;23, 181 anti-ischemic agents, l7, 71 antimalarial inhibitors, 3, 159 antimetabolite concept, drug design, 11, 223 antimicrobial drugs - clinical problems and opportunities, 21, 119
Cumulative
Chapter
Tiles
Keyword
Index,
Vol.
l-36
antimicrobial potentiation, 33, 121 antimicrobial peptides, 27, 159 antimitotic agents, 34, 139 antimycobacterial agents, 3J, 161 antineoplastics, 2, 166; 3, 150; 4, 154; 5, 144; 1, 129; 8, 128; 9, 139; l0, 131; VI, 110; l2, 120; l3, 120; l4, 132; l5, 130; l6, 137; IJ, 163; I& 129; IJ, 137; 20, 163; 22, 137; 24, 121; 28, 167 antiparasitics, 1, 136, 150; 2, 131, 147; 3, 126, 140; 4, 126; 5, 116; 1, 145; 6, 141; 9, 115; lo, 154; 11, 121; l2, 140; l3, 130; 14, 122; l5, 120; I& 125; l7, 129; l9, 147; 26, 161 antiparkinsonism drugs, 6, 42; 9, 19 antiplatelet therapies, 35, 103 antipsychotics, 1, 1; 2, 1; 3, 1; 4, 1; 5, 1; 6, 1; 1, 6; 8, 1; 9, 1: IO, 2; lJ, 3; 2, 1; l3,11;l4,12;15,12;l& 11;~,21;19,21;2l, 1;22,1;23,1;24,1;~, l;B, 53; 27,49; 2a, 39; 33,l antiradiation agents, ‘l, 324; 2, 330; 3, 327; 5, 346 anti-retroviral chemotherapy, 25, 149 antiretroviral drug therapy, 32, 131 antiretroviral therapies, 35, 177; 36, 129 antirheumatic drugs, l6, 171 antisense oligonucleotides, 23, 295; 33, 313 antisense technology, 29, 297 antithrombotics, 7, 78; 8, 73; 9, 75; l0, 99; l2, 80; 14, 71; l7, 79; 27, 99; 32, 71 antithrombotic agents, 29, 103 antitumor agents, 3, 121 antitussive therapy, S, 31 antiviral agents, ?_, 129; 2, 122; 3, 116; 4, 117; 5, 101; 5, 118; 7, 119; 6, 150; 9, 128; IO, 161; IJ, 128; l3, 139; l5, 149; 16, 149; 18, 139; 19, 117; 22, 147; 23, 161; 24, 129; 26, 133; 28, 131; 29, 145; 30, 139; 2, 141; 33, 163 antitussive therapy, 35, 53 anxiolytics, 26, 1 apoptosis, 31, 249 aporphine chemistry, 4, 331 arachidonate lipoxygenase, 16, 213 arachidonic acid cascade, l2, 182; 14, 178 arachidonic acid metabolites, IJ, 203; 23, 181; 3, 71 arthritis, l3, 167; l6, 189; l7, 175; l8, 171; 2J, 201; 23, 171, 181; 3,203 arthritis, immunotherapy, 23, 171 aspartyl proteases, x, 247 asthma, 29, 73; 32, 91 asymmetric synthesis, IJ, 282 atherosclerosis, 1, 178; 2, 187; 3, 172; 4, 178; 5, 180; 6, 150; I, 169; 8, 183; 15, 162; l8, 161; 21, 189; 3, 147; 25, 169; 28, 217; 2, 101; 3, 101; 36, 57 atherothrombogenesis, 31, 101 atrial natriuretic factor, 21, 273; 23, 101 autoimmune diseases, 34, 257 autoreceptors, 19, 51 bacterial adhesins, 2L3, 239
353 -
-354
Cumuiatlve
Chapter
Titles
Keyword
Index,
Vol. 1-36
bacterial genomics, 32, 121 bacterial resistance, lJ, 239; 17, I 19; 32, I I I bacterial toxins, l2, 211 bacterial virulence, 30, 111 basophil degranulation, biochemistry, lJ, 247 Bcl2 family, 3l, 249; 33, 253 behavior, serotonin, 7, 47 benzodiazepine receptors, l6, 21 bioinformatics, 36, 201 bioisosterism, 2l, 283 biological factors, IO, 39; II, 42 biological membranes, 11, 222 biopharmaceutics, 1, 331; 2, 340; 3, 337; 4, 302; 5, 313; 6, 264; 7, 259; & 332 biosensor, 30,275 biosynthesis, antibotics, l2, 130 biotechnology, drug discovery, 25, 289 blood-brain barrier, 3, 305 blood enzymes, 1,233 bone, metabolic disease, l2, 223; l5, 228; lJ, 261; 22, 169 bone metabolism, 26, 201 brain, decade of, 27, 1 calcium antagonists/modulators, l6, 257; l7, 71; 18, 79; 2_1, 85 calcium channels, 30, 51 calmodulin antagonists, SAR, I& 203 cancer, 27, 169; 31,241; 34, 121; 35, 123; 3, 167 cancer chemotherapy, 29, 165 cancer cytotoxics, 33, 151 cancer, drug resistance, 23, 265 cancer therapy, 2, 166; 3, 150; 4, 154; 5, 144; 1, 129; 8, 128; 9, 139, 151; a, 131; II, 110; l2, 120; l3, 120; l4, 132; l5, 130; l6, 137; l7, 163; l8, 129; 2l, 257; 23, 151 cannabinoid receptors, 9, 253; 34, 199 carbohydrates, 27, 301 carboxylic acid, metalated, l2, 278 carcinogenicity, chemicals, l2, 234 cardiotonic agents, l3, 92; ‘IJ, 93; l9, 71 cardiovascular, l0, 61 caspases, 33, 273 catalysis, intramolecular, 1, 279 catalytic antibodies, 25, 299; 30, 255 cell adhesion, 29, 215 cell adhesion molecules, 25, 235 cell based mechanism screens, 28, 161 cell cycle, 3l, 241; 3, 247 cell cycle kinases, 36, 139 cell invasion, l4, 229 cell metabolism, 1, 267 cell metabolism, cyclic AMP, 2, 286
Cumulative
Chapter
TEles
Keyword
Index,
355 -
Vol. 1-36
cellular responses, inflammatory, l2, 152 chemoinformatics, 33, 375 chemokines, 3,209; 35,191 chemotaxis, l5, 224; l7, 139, 253; 24, 233 cholecystokinin, l-8, 31 cholecystokinin agonists, 3, 191 cholecystokinin antagonists, 26, 191 cholesteryl ester transfer protein, 35, 251 chronopharmacology, II, 251 circadian processes, 27, 11 coagulation, 26, 93; 33, 81 cognition enhancers, 25, 21 cognitive disorders, l9, 31; 21, 31; 23, 29; 31, 11 collagenase, biochemistry, 25, 177 collagenases, 19,231 colony stimulating factor, 21, 263 combinatorial chemistry, 34, 267; 34, 287 combinatorial libraries, 3l, 309; 3l, 319 combinatorial mixtures, 32, 261 complement cascade, 27? 199 complement inhibitors, l5, 193 complement system, 7,228 conformation, nucleoside, biological activity, 5, 272 conformation, peptide, biological activity, X3, 227 conformational analysis, peptides, 23, 285 congestive heart failure, 22, 85; 35, 63 contrast media, NMR imaging, 24, 265 corticotropin-releasing factor, 25, 217; 30, 21; 34, 11 corticotropin-releasing hormone, 32, 41 cotransmitters, 20, 51 cyclic AMP, 2, 286; 6, 215; 8, 224; IJ, 291 cyclic GMP, 11, 291 cyclic nucleotides, 9, 203; 10, 192; l5, 182 cyclin-dependent kinases, 32, 171 cyclooxygenase, 30, 179 cyclooxygenase-2 inhibitors, 32, 211 cysteine proteases, 35, 309 cystic fibrosis, 27, 235; 36, 67 cytochrome P-450,9, 290; l9, 201; 32, 295 cytokines, 27, 209; 31, 269; 34, 219 cytokine receptors, 26, 221 database searching, 3D, 28,275 DDT-type insecticides, 9, 300 dermal wound healing, 24, 223 dermatology and dermatological agents, 12, 162; 18, 181; 2, 201; 3, 177 designer enzymes, 25, 299 diabetes, 9, 182; 11, 170; l3, 159; 19, 169; 22,213; 25, 205; 2, 159; a,21 Diels-Alder reaction, intramolecular, 9, 270
3
356
Cumulatloe
Chapter
Tales
Keyword
distance geometry, 26, 281 diuretic, 1, 67; 2, 59; 3, 62; S, 88; 8, 83; 10, 71; II, DNA binding, sequence-specific, 21, 311; 22, 259 DNA vaccines, 34, 149 docking strategies, 26, 275 dopamine,l3,11;H,12;15,12;~,11,103;~,21;~,41;~,107 dopamine D3,29,43 dopamine D4,29,43
Index,
Vol. 136
71; 13, 61; 15, 100
DPP-IV Inhibition, 3, 191 drug abuse, CNS agents, 9, 38 drug allergy, 3, 240 drug carriers, antibodies, l5, 233 drug carriers, liposomes, 14, 250 drug delivery systems, 15, 302; 18, 275; 20, 305 drug design, 34, 339 drug design, computational, 33, 397 drug design, metabolic aspects, 23, 315 drug discovery, l7, 301; 34, ; 34, 307 drug disposition, l5, 277 drug metabolism, 3, 227; 4, 259; 5, 246; f3, 205; 8, 234; 9, 290; IJ, 190; 12, 201 l3, 196, 304; 14, 188; l6, 319; l7, 333; 23, 265, 315; 29, 307 drug receptors, 25, 281 drug resistance, 23, 265 EDRF, 27,69 elderly, drug action, 20, 295 electrospray mass spectrometry, 32, 269 electrosynthesis, IJ, 309 enantioselectivity, drug metabolism, l3, 304 endorphins, IJ, 41; l4, 31; 15, 32; s,41; IJ, 21; IJ, 51 endothelin, 3l, 81; 32, 61 endothelin antagonism, 35, 73 endothelin antagonists, 29, 65, 30, 91 enzymatic monooxygenation reactions, l5, 207 enzyme inhibitors, 1, 249; 9, 234; l3, 249 enzyme immunoassay, 18,285 enzymes, anticancer drug resistance, 23, 265 enzymes, blood, 1, 233 enzymes, proteolytic inhibition, l3, 261 enzyme structure-function, 22, 293 enzymic synthesis, 19, 263; 23, 305 epitopes for antibodies, 2JI 189 erectile dysfunction, 3, 71 estrogen receptor, 31, 181 ethnobotany, 29, 325 excitatory amino acids, 22, 31; 24, 41; 3, 11; 29, 53 ex-vivo approaches, 35, 299 factor Xa, 3, 51; 34, 81 factor Xa inhibitors, 35, 83
Cumulative
Chapter Titles Keyword
Index, Vol. l-36
fertility control, IJ, 240; l4, 168; 21, 169 filiarial nematodes, 35, 281 forskolin, l9, 293 free radical pathology, a, 257; 22, 253 fungal resistance, 35, 157 G-proteins, 23, 235 GABA, antagonists, l3, 31; 15, 41 galanin receptors, 33, 41 gamete biology, fertility control, l0, 240 gastrointestinal agents, 1, 99; 2, 91; 4, 56; 6> 68; 8, 93; 10. 90; 12, 91; 16, 83; l7,89; 1_8,89; a,1 17; 23,201 gender based medicine, 33, 355 gene expression, 32, 231 gene expression, inhibitors, 23, 295 gene targeting technology, 29, 265 gene therapy, 8, 245; 30, 219 genetically modified crops, 3, 357 gene transcription, regulation of, 27, 311 genomics, 34, 227 glucagon, 34, 189 glucagon, mechanism, l8, 193 f&D-glucans, 3, 129 glucocorticosteroids, IJ, 179 glutamate, 31, 31 glycoconjugate vaccines, 28, 257 glycopeptide antibiotics, 3l, 131 glycoprotein Ilb/llla antagonists, 28, 79 glycosylation, non-enzymatic, 14, 261 gonadal steroid receptors, 3, 11 gonadotropin releasing hormone, 0, 169 GPllb/llla, 31, 91 G protein-coupled receptors, 35, 271 growth factor receptor kinases, 3Ji, 109 growth factors, 21, 159; 24, 223; 28, 89 growth hormone, 20, 185 growth hormone secretagogues, 28, 177; 32, 221 guanylyl cyclase, 27, 245 hallucinogens, 1, 12; 2, 11; 3, 14; 4, 13; 5, 23; 6, 24 HDL cholesterol, 35, 251 heart disease, ischemic, l5, 89; l7, 71 heart failure, l3, 92; l6, 93; 22, 85 helicobacter pylori, 30, 151 hemoglobinases, 34, 159 hemorheologic agents, IJ, 99 herbicides, 17, 311 heterocyclic chemistry, 14, 278 high throughput screening, 33, 293 histamine HJ receptor agents, 33, 31
357 -
358 -
Cumulative
Chapter
Titles
Keyword
Index.
Vol. 1-36
HIV co-receptors, 33, 263 HIV protease inhibitors, S, 141; 29, 123 HIV reverse transcriptase inhibitors, 3, 123 HIV vaccine, 27, 255 homeobox genes 27,227 hormones, glycoprotein, l2, 211 hormones, non-steroidal, 1, 191; 3, 184 hormones, peptide, 5, 210; 1, 194; 6, 204; lJ, 202; II, 158; l6, 199 hormones, steroid, 1, 213; 2, 208; 3, 207; 3, 199 host modulation, infection, 8, 160; 14, 146; 18, 149 human gene therapy, 26, 315; 3,267 human retrovirus regulatory proteins, S, 171 !Shydroxytryptamine, 2, 273; 1, 47; 21, 41 hypercholesterolemia, 24, 147 hypersensitivity, delayed, 8, 284 hypersensitivity, immediate, 1, 238; 8, 273 hypertension, 2%, 69 hypertension, etiology, 9, 50 hypnotics, 1, 30; 2, 24; 3, 2%; 4, 28; z, 39; & 29; IJ, 30; II, 13; l2, ~,22;~,22,~;31;~,11;~,11;~,11;~,11 ICE gene family, 31,249 IgE, I& 247 immune mediated idiosyncratic drug hypersensitivity, 26, 181 immune system, 3,281 immunity, cellular mediated, l7, 191; I%, 265 immunoassay, enzyme, I%, 285 immunomodulatory proteins, 35, 281 immunophilins, 2%, 207 immunostimulants, arthritis, IJ, 13%; l4, 146 immunosuppressants, 26,211; 2, 175 immunosuppressive drug action, 28, 207 immunosuppressives, arthritis, IJ, 13% immunotherapy, cancer, 9, 151; 23, 151 immunotherapy, infectious diseases, I& 149; 22, 127 immunotherapy, inflammation, 23, 171 infections, sexually transmitted, l4, 114 inflammation, 22, 245; 3J, 279 inflammation, immunomodulatory approaches, 23, 171 inflammation, proteinases in, 2%, 187 inflammatory bowel disease, 3, 167 inhibitors, complement, 15, 193 inhibitors, connective tissue, l7, 175 inhibitors, enzyme, l3, 249 inhibitors, irreversible, 9, 234; l6, 289 inhibitors, platelet aggregation, 6, 60 inhibitors, proteolytic enzyme, IJ, 261 inhibitors, renin-angiotensin, 13, 82 inhibitors, reverse transcription, 8, 251
10; l3, 21
Cumulative
Chapter
Tkles
Keyword
Index.
Vol. 1-36
inhibitors, transition state analogs, z, 249 inorganic chemistry, medicinal, 8, 294 inosine monophosphate dehydrogenase, 35,201 inositol triphosphate receptors, 27, 261 insecticides, 9, 300; 17, 3 11 insulin, mechanism, l6, 193 integrins, 3, 191 62 -integrin Antagonist, S, 181 integrin alpha 4 beta 1 (VLAd), 34, 179 intellectual property, 36, 331 interferon, 8, 150; l2, 211; Is, 229; l7, 151 interleukin-1 , 20, 172; 22, 235; 3, 185; 29, 205, 33, 183 interleukin-2, l9, 191 interoceptive discriminative stimuli, animal model of anxiety, 15, 51 intramolecular catalysis, 7, 279 ion channels, ligand gated, 25, 225 ion channels, voltage-gated, 25, 225 ionophores, monocarboxylic acid, IO, 246 iron chelation therapy, l3, 219 irreversible ligands, 25, 271 ischemialreperfusion, CNS, 27, 31 ischemic injury, CNS, 25, 31 isotopes, stable, l2, 319; l9, 173 JAKs, 2,269 l3-lactam antibiotics, 11, 271; l2, 101; l3, 149; 20, 127, 137; 23, 121; 24, 101 &lactamases, l3, 239; l7, 119 ketolide antibacterials, 35, 145 LDL cholesterol, 35, 251 learning, 3, 279; 16, 51 leptin, 2, 21 leukocyte elastase inhibitors, 3, 195 leukocyte motility, l7, 181 leukotriene modulators, 32, 91 leukotrienes, l7, 291; l9, 241; 3, 71 LHRH, 20,203; 23,211 lipid metabolism, 9, 172; 10, 182; 11, 180; l2, 191; 13, 184; 14, 198; l5, 162 lipoproteins, 3, 169 liposomes, l4, 250 lipoxygenase, I& 213; 17,203 lymphocytes, delayed hypersensitivity, 8, 284 macrocyclic immunomodulators, 25, 195 macrolide antibacterials, 35, 145 macrolide antibiotics, 25, 119 macrophage migration inhibitor factor, 33, 243 magnetic resonance, drug binding, II, 311 malaria, 3l, 141; 34, 349 male contraception, 32, 191 managed care, 30,339
359 -
-360
Cumulative
Chapter
Titles
Keyword
Index,
Vol. 1-36
MAP kinase, 3l, 289 market introductions, l9, 313; 20, 315; 21, 323; 22, 315; 23, 325; 3, 295; 25, 30% 26,297; 223 321; 28,325; 29,331; 30,295; 31, 337; 2,305; 3, 327 mass spectrometry, 3l, 319; 34, 307 mass spectrometiy, of peptides, 24, 253 mass spectrometry, tandem, 2l, 213; 21, 313 mast cell degranulation, biochemistry, I& 247 matrix metailoproteinase inhibitors, 35, 167 mechanism based, anticancer agents, 25, 129 mechanism, drug allergy, 3, 240 mechanisms of antibiotic resistance, 1, 217; l3, 239; l7, 119 medicinal chemistry, 26, 34330, 329; 33, 385; 3,267 melatonin, 2, 31 membrane function, 10, 317 membrane regulators, II, 210 membranes, active transport, II, 222 memory, 3, 279; l2, 30; %,51 metabolism, cell, 1, 267; 2, 286 metabolism, drug, 3, 227; 4, 259; 5, 246; 6, 205; f3, 234; 9, 290; 11, 190; l2, 201; l3, 196,304; 14, 188; 23, 265, 315 metabolism, lipid, 9, 172; IO, 182; II, 180; 12, 191; l4, 198 metabolism, mineral, l2, 223 metabotropic glutamate receptor, 35, 1 metal carbonyls, 8, 322 metalloproteinases, 31, 231; 33, 131 metals, disease, l4, 321 metastasis, 26, 151 microbial products screening, 21, 149 migraine, 22, 41; 32, 1 mitogenic factors, 2J 237 modified serum lipoproteins, 25, 169 molecular diversity, 26, 259, 271; 2& 315; 34, 287 molecular modeling, 2, 269; 23, 285 monoclonal antibodies, l6, 243; 27, 179; 29, 317 monoclonal antibody cancer therapies, 3, 237 monoxygenases, cytochrome P-450,9, 290 multivalent ligand design, 35, 321 muscarinic agonists/antagonists, 23, 81; 3, 31; 29, 23 muscle relaxants, 1, 30; 2, 24; 3, 28; 3, 28; 8, 37 muscular disorders, IJ, 260 mutagenicity, mutagens, l2, 234 mutagenesis, SAR of proteins, 18, 237 myocardial ischemia, acute, 25, 71 narcotic antagonists, 7, 31; 8, 20; 9, 11; IJ, 12; IJ, 23; IJ, 41 natriuretic agents, l9, 253 natural products, 5, 274; 15, 255; l7, 301; 26, 259; 32, 285 natural killer cells, l8, 265 neoplasia, 8, 160; IJ, 142
Cumulative
Chapter
Titles
Keyword
Index,
Vol. 1-36
neurodegeneration, 30, 31 neurodegenerative disease, 28, 11 neurokinin antagonists, 26, 43; 31 111; 32, 51; 33, 71; 34, 51 neurological disorders, 31, 11 neuronal calcium channels, 3, 33 neuronal cell death, 29, 13 neuropeptides, 21, 51; 22, 51 neuropeptide Y, 3J, 1; 32, 21; 34, 31 neuroprotection, 29, 13 neurotensin, l7, 31 neurotransmitters, 3, 264; 4, 270; l2, 249; l4, 42; IJ, 303 neutrophic factors, 26, 245; 28, 11 neutrophil chemotaxis, 24, 233 nicotinic acetylcholine receptor, 22, 281; 35, 41 nitric oxide synthase, 29, 83; 31, 221 NMR, 27,271 NMR in biological systems, 20, 267 NMR imaging, 20,277; 2fl, 265 NMR methods, 31, 299 NMR, protein structure determination, 23, 275 non-enzymatic glycosylation, 14, 261 non-HIV antiviral agents, 36, 119 non-nutritive, sweeteners, l7, 323 nonpeptide agonists, 32, 277 non-steroidal antiinflammatories, 1, 224; 2, 217; 3, 215; 4, 207; 5, 225; 6, 182; 7, 208; 6,214; 9, 193; IO, 172; 13, 167; ‘l6, 189 novel analgesics, 35, 21 nuclear orphan receptors, 32, 251 nucleic acid-drug interactions, ‘lJ, 316 nucleic acid, sequencing, l6, 299 nucleic acid, synthesis, 16, 299 nucleoside conformation, 5, 272 nucleosides, 1, 299; 2, 304; 3, 297; 5, 333 nucleotide metabolism, 21, 247 nucleotides, 1, 299; 2, 304; 3, 297; 5, 333 nucleotides, cyclic, 9, 203; IO, 192; 15, 182 obesity, 1, 51; 2, 44; 3, 47; 5, 40; 8, 42; IJ, 200; l5, 172; 19, 157; 23, 191; 31, 201; 32,21 oligomerisation, 35, 271 oligonucleotides, inhibitors, 23, 295 oncogenes, 18,225; 21, 159,237 opioid receptor, IJ, 33; l2, 20; l3, 41; l4, 31; l5, 32; l6, 41; u, 21; l& 51; 20, 21; 2l, 21 opioids, 2, 20; l6,41; IJ, 21; 18, 51; 3, 21; 21, 21 opportunistic infections, 29, 155 oral pharmacokinetics, 35, 299 organocopper reagents, IJ, 327 osteoarthritis, 22, 179
361 -
-362
Cumulative
Chapter
Titles
Keyword
Index,
Vol. l-36
osteoporosis, 22, 169; 26, 201; 3, 275; 3l, 211 oxazolidinone antibacterials, 35, 135 P-glycoprotein, multidrug transporter, 25, 253 parallel synthesis, 3, 267 parasite biochemistry, &3, 269 parasitic infection, 36, 99 patents in medicinal chemistry, 22, 331 pathophysiology, plasma membrane, 10, 213 PDE IV inhibitors, 2, 71 penicillin binding proteins, 18, 7 19 Peptic Ulcer, 1, 99; 2, 91; 4, 56; 6, 68; ~3, 93; l0, 90; 12, 91; l6, 83; l7, 89; I& 89; l9, 81; 20,93; 22, 191; 25, 159 peptide-l , 34, 189 peptide conformation, l3, 227; 23, 285 peptide hormones, 5, 210; 7, 194; 8,204; IJ, 202; IJ, 158,l9, 303 peptide hypothalamus, 1, 194; 8, 204; 10, 202; l-6, 199 peptide libraries, 26, 271 peptide receptors, 25, 281; 32, 277 peptide, SAR, 5, 266 peptide stability, 26, 285 peptide synthesis, 5, 307; z, 289; l6, 309 peptide synthetic, 1, 289; 2, 296 peptide thyrotropin, l7, 31 peptidomimetics, 24, 243 periodontal disease, l0, 228 PET, 24,277 PET ligands, 36, 267 pharmaceutics, ‘l, 331; 2, 340; 3, 337; 4, 302; 5, 313; 5, 254, 264; 1, 259; 6, 332 pharmaceutical proteins, &I, 237 pharmacogenetics, 2,261 pharmacogenomics, 34, 339 pharmacokinetics, 5, 227, 337; 4, 259, 302; 5, 246, 313; 6, 205; 8, 234; 9, 290; IJ, 190; 12,201; l3, 196,304; l4, 188,309; 16,319; II, 333 pharmacophore identification, 15, 267 pharmacophoric pattern searching, 14, 299 phosphodiesterase, 31, 61 phosphodiesterase 4 inhibitors, 29, 185; 33, 91; 36, 41 phospholipases, 19,213; 22,223; 24, 157 physicochemical parameters, drug design, 3, 348; 4, 314; 2, 285 pituitary hormones, 7, 194; 8, 204; l0, 202 plants, 34, 237 plasma membrane pathophysiology, IO, 213 plasma protein binding, 31, 327 plasminogen activator, 18, 257; 20, 107; 23, 111; 34, 121 plasmon resonance, 33,301 platelet activating factor (PAF), l7, 243; 20, 193; 24, 81 platelet aggregation, 6, 60 polyether antibiotics, IO, 246
Cumulative
Chapter
Titles
Keyword
Index.
Vol
1-36
polyamine metabolism, l7, 253 polyamine spider toxins, 24, 287 polymeric reagents, II, 281 positron emission tomography, 24, 277, 25, 261 potassium channel activators, 3, 73 potassium channel antagonists, 27, 89 potassium channel blockers, 32, 181 potassium channel openers, 24, 91,=, 81 potassium channel modulators, 36, 11 privileged structures, 35, 289 prodrugs, 10, 306; 22, 303 profiling of compound libraries, 36, 277 programmed cell death, 3, 239 prolactin secretion, l5, 202 prostacyclin, 14, 178 prostaglandins, 3, 290; 5, 170; 6, 137; 7, 157; 8, 172; 9, 162; IJ, 80 prostanoid receptors, 33, 223 prostatic disease, 24, 197 proteases, 26, 151 proteasome, 3l, 279 protein C, 29, 103 protein growth factors, l7, 219 proteinases, arthritis, l4, 219 protein kinases, l8, 213; 29, 255 protein kinase C, 20, 227; 23, 243 protein phosphatases, 29, 255 protein structure determination, NMR, 23, 275 protein structure prediction, 36, 211 protein structure project, 31, 357 protein tyrosine kinases, 27, 169 protein tyrosine phosphatase, 35, 231 proteomics, 36, 227 psoriasis, l2, 162; 32, 201 psychiatric disorders, 11, 42 psychoses, biological factors, IO, 39 psychotomimetic agents, 9, 27 pulmonary agents, 1, 92; 2, 83; 3, 84; 4, 67; 5, 55; z, 89; 9, 85; I& 80; II, 51; IZ, 70; l3, 51; l4, 51; l5, 59; IJ, 51; l& 61; 2J. 71; 21, 73; 22, 73; 23, 69; 24, 61; 25, 61; 26, 113; 27, 109 pulmonary disease, 34, 111 pulmonary inflammation, 3J, 71 purinoceptors, 3l, 21 quantitative SAR, 5, 245; 8, 313; 11, 301; IJ, 292; 17, 281 quinolone antibacterials, 2_1, 139; 22, 117; 3, 133 radioimmunoassays, IO, 284 radioisotope labeled drugs, 7* 296 radioimaging agents, l8, 293 radioligand binding, l9, 283
363 -
364 -
Cumulative
Chapter
Txles
Keyword
Index,
Vol. 1-36
radiosensitizers, 2& 151 ras farnesyltransferase, 1, 171 ras GTPase, 3,249 ras oncogene, 29, 165 receptor binding, 12, 249 receptor mapping, 14, 299; 15, 267; 23, 285 receptor modeling, 2, 281 receptor, concept and function, 2J, 211 receptors, acetylcholine, 30, 41 receptors, adaptive changes, l9, 241 receptors, adenosine, 28, 295; 33, 111 receptors, adrenergic, l5, 217 receptors, f3-adrenergic blockers, 14, 81 receptors, benzodiazepine, l6, 21 receptors, cell surface, l2, 211 receptors, drug, 1, 236; 2, 227; 8, 262 receptors, G-protein coupled, 23, 221, 27, 291, receptors, G-protein coupled CNS, 28, 29 receptors, histamine, 14, 91 receptors, muscarinic, 24, 31 receptors, neuropeptide, 28? 59 receptors, neuronal BZD, 28, 19 receptors, neurotransmitters, 3, 264; l2, 249 receptors, neuroleptic, 12, 249 receptors, opioid, ll, 33; l2, 20; l3, 41; l4, 31; 15, 32; Is, 41; l7, 21 receptors, peptide, 25, 281 receptors, serotonin, 23, 49 receptors, sigma, 28, 1 recombinant DNA, 17,229; l8, 307; 19,223 recombinant therapeutic proteins, 3, 213 renal blood flow, 16, 103 renin, l3, 82; 20, 257 reperfusion injury, 22, 253 reproduction, 1, 205; 2, 199; 3, 200; 4, 189 resistant organisms, 34, 169 retinoids, 3, 119 reverse transcription, 8, 251 RGD-containing proteins, 28, 227 rheumatoid arthritis, II, 138; l4, 219; l8, 171; 21, 201; 23, 171, 181 ribozymes, 30,285 SAR, quantitative, 5, 245; 8, 313; IJ, 301; l3, 292; lJ, 291 same brain, new decade, 36, 1 secretase inhibitors, 35, 31; sedative-hypnotics, 7, 39; 8, 29; lJ, 13; lJ, 10; l3, 21; VJ, 22; l5, 22; 16, 31; u ll;B, 11,l9,11;2J, 11 sedatives, 1, 30; 2, 24; 3, 28; 4, 28; 7, 39; 8, 29; lJ, 30; lJ, 13; lJ, 10; l3, 21 ~,22;~;22;~,31;~, ll;B, 11;2CJ, 1;2J, 11 sequence-defined oligonucleotides, 26, 287
Cumulative
Chapter
Tnles
Keyword
Index,
Vol. l-36
serine proteases, 32, 71 SERMs, 36, 149 serotonergics, central, 25, 41; 27, 21 serotonin, 2, 273; 1, 47; 26, 103; 3, 1; 33, 21 serotonin receptor, 35, 11 serum lipoproteins, regulation, lJ, 184 sexually-transmitted infections, 14, 114 SH2 domains, 0,227 SH3 domains, 3,227 silicon, in biology and medicine, 10, 265 sickle cell anemia, 20, 247 signal transduction pathways, 33, 233 skeletal muscle relaxants, 6, 37 sleep, 27, 11; 34, 41 slow-reacting substances, ‘l5, 69; l6, 213; l7, 203, 291 sodium/calcium exchange, 20, 215 sodium channels, 33, 51 solid-phase synthesis, 31, 309 solid state organic chemistry, 20, 287 solute active transport, lJ, 222 somatostatin, l4, 209; l8, 199; 3, 209 spider toxins, 3, 287 SRS, l5,69; l6, 213; l7, 203, 291 STATS,, 269 stereochemistry, 25, 323 steroid hormones, 1, 213; 2, 208; 3, 207; 4, 199 stroidogenesis, adrenal, 2, 263 steroids, 2, 312; 3, 307; 3, 281; 5, 192, 296; 6, 162; 1, 182; 6, 194; ‘lJ, 192 stimulants, 1, 12; 2, 11; 3, 14; 4, 13; 5, 13; 6, 15; 1, 18; 8, 11 stroke, pharmacological approaches, 2J, 108 stromelysin, biochemistry, 25, 177 structure-based drug design, 27, 271; 30, 265; 3, 297 substance P, l7, 271; l8, 31 substituent constants, 2, 347 suicide enzyme inhibitors, 16, 289 superoxide dismutases, 10, 257 superoxide radical, l0, 257 sweeteners, non-nutritive, l7, 323 synthesis, asymmetric, lJ, 282 synthesis, computer-assisted, 2, 288; I& 281; 21, 203 synthesis, enzymic, 23, 305 T-cells, 27, 189; 33, 199; 34, 219 tachykinins, 28, 99 taxol, 28, 305 technology, providers and integrators, 3, 365 thalidomide, 30, 319 therapeutic antibodies, 36, 237 thrombin, 30, 71, 31, 51; 34, 81
365
366 -
Cumulative
Chapter
Titles
Keyword
thrombolytic agents, 29, 93 thrombosis, 5, 237; S, 93; 33, 81 thromboxane receptor antagonists, 25, 99 thromboxane synthase inhibitors, 25, 99 thromboxane synthetase, 22, 95 thromboxanes, l4, 178 thyrotropin releasing hormone, l7, 31 TNF-cx, 32, 241 topoisomerase, 2J, 247 toxicity reversal, 15, 233 toxicity, mathematical models, 18, 303 toxicology, comparative, ll, 242; 33, 283 toxins, bacterial, l2, 211 transcription factor NF-~8, 29, 235 transcription, reverse, 8, 251 transgenic animals, 24, 207 transgenic technology, 29, 265 translational control, 29, 245 traumatic injury, CNS, 25, 31 trophic factors, CNS, 27, 41 tumor necrosis factor, 22, 235 type 2 diabetes, 35, 211 tyrosine kinase, 30, 247; 31, 151 urokinase-type plasminogen activator, 34, 121 vascular proliferative diseases, 30, 61 vasoactive peptides, 25, 89; 3, 83; 27, 79 vasoconstrictors, 3, 77 vasodilators, 4, 77; l2, 49 vasopressin antagonists, 23, 91 vasopressin receptor modulators, 36, 159 veterinary drugs, l6, 161 viruses, l4, 238 vitamin D, lO,295; 15,288; l7, 261; l9, 179 waking functions, l0, 21 water, structures, 5, 256 wound healing, 24, 223 xenobiotics, cyclic nucleotide metabolism, I& 182 xenobiotic metabolism, 23, 315 x-ray crystallography, 2l, 293; 27, 271
Index,
Vol. 1-36
CHAPTER TITLES KEYWORD INDEX. VOLUMES l-36
acetylcholine receptors, 30, 41 acetylcholine transporter, 28, 247 adenylate cyclase, S, 227, 233; l2, 172; 19, 293; 29, 287 adenosine, 33, 111 adenosine, neuromodulator, l8, 1; 23, 39 adjuvants, 9, 244 ADME by computer, 36,257 ADME properties, 34, 307 adrenal steroidogenesis, 2, 263 adrenergic receptor antagonists, 35, 221 I3-adrenergic blockers, IO, 51; 14, 81 t3-adrenergic receptor agonists, 33, 193 affinity labeling, 9, 222 l33-agonists, 3J, 189 AIDS, 23, 161,253; 25, 149 alcohol consumption, drugs and deterrence, 3, 246 aldose reductase, l9, 169 alkaloids, 1, 311; 3, 358; 4, 322; 5, 323; 6, 274 allergic eosinophilia; 34, 61 allergy, 29, 73 alopecia, 24, 187 Alzheimer’s Disease, 2, 229; 3, 49, 197, 247; 32, 11; 34, 21; 3, 31 aminocyclitol antibiotics, l2, 110 t3-amyloid, 2, 21 amyloid, 28, 49; 32, 11 amyloidogenesis, 26, 229 analgesics (analgetic), 1, 40; 2, 33; 3, 36; 4, 37; 5, 31; 6, 34; 7, 31; 6, 20; 9, 11; IO, 12; II, 23; l2, 20; l3, 41; l4, 31; l5, 32; I& 41; l7, 21; l8, 51; IJ, 1; 20, 21;2J,21;23,11;25,11;3J, 11;33,11 androgen action, 21, 179; 29, 225 androgen receptor modulators, 36, 169 anesthetics, 1, 30; 2, 24; 3, 28; 4, 28; 1, 39; 8, 29; IJ, 30, 31, 41 angiogenesis inhibitors, 27, 139; 32, 161 angiotensinlrenin modulators, 26, 63; 27, 59 animal engineering, 29, 33 animal healthcare, 36, 319 animal models, anxiety, l5, 51 animal models, memory and learning, l2, 30 Annual Reports in Medicinal Chemistry, 25, 333 anorexigenic agents, ‘l, 51; 2, 44; 3, 47; 5, 40; 8, 42; lJ, 200; l5, 172 antagonists, calcium, l& 257; l7, 71; l8, 79 antagonists, GABA, l3, 31; l5, 41 antagonists, narcotic, 1, 31; 8, 20; 9, 11; l& 12; lJ, 23 antagonists, non-steroidal, 1, 213; 2, 208; 3, 207; 4, 199 antagonists, steroidal, 1, 213; 2, 208; 3, 207; 4, 199 anthracycline antibiotics, 14, 288 antiaging drugs, 9, 214
351 -
352
Cumulative
Chapter
Titles
Keyword
Index,
Vol. l-36
antiallergy agents, 1, 92: 2, 83; 3, 84; 7, 89; 9, 85; Q, 80; ll, 51; 12, 70; l3, 51; 14, 51; 15, 59; II, 51; 18, 61; 19, 93; 20% 71; 2l, 73; 22, 73; 3, 69; 24, 61; 25, 61; 26, 113; 27, 109 antianginals, 1, 78; 2, 69; 3, 71; 5, 63; I, 69; 8, 63; 9, 67; l2, 39; l7, 71 anti-angiogenesis, 2, 123 antianxiety agents, 1, 1; 2, 1; 3, 1; 4, 1; 51, 1; S, 1; 1, 6; 8, 1; 9, 1; IO, 2; 11, 13; ~,10;~,21;~,22;~,22;~,31;~,11;~,11;~,11;~,1;~,11;~,11; 23,19; a,11 antiarrhythmics, 1, 85; 6, 80; 8, 63; !3, 67; 2, 39; l8, 99, 21, 95; 25, 79; 27, 89 antibacterial resistance mechanisms, 28, 141 antibacterials, 1, 118; 2, 112; 3, 105; 3, 108; 5, 87; 6, 108; l7, 107; l8, 29, 113; 23, 141; 3J 101; 3l, 121; 33, 141; 34, 169; 34, 227: 3&89 antibiotic transport, 3, 139 antibiotics, 1, 109; 2, 102; 3, 93; 4, 88; 5, 75, 156: 6> 99; 7, 99, 217; i& 104; 9, 95; IO, 109, 246; IJ, 89; IJ, 271; 12, 101, 110; l3, 103, 149; l4, 103; lfj, 106; l7,107; 18,109; 2l/ 131; 23,121; 24,101; 25,119 antibiotic producing organisms, 27, 129 antibodies, cancer therapy, 23, 151 antibodies, drug carriers and toxicity reversal, IJ, 233 antibodies, monoclonal, 16, 243 anticancer agents, mechanical-based, 25, 129 anticancer drug resistance, 23, 265 anticoagulants, 3, 81; 36, 79 anticoagulant agents, 3, 83 anticonvulsants, 1, 30; 2, 24; 3, 28; 4, 28; 1, 39, 6, 29; IO, 30; IJ, 13; l2, 10; IJ, 21;~,22;~,22;~,31;~,11;~,11;~,11;~,11;~,11;~,19;~,11 antidepressants, ‘l, 12; 2, 11; 3, 14; 3, 13; 5, 13; 6, 15; 1, 18; 6, 11; 11, 3; 2, 1; l3, 1; l4, 1; IJ, 1; I& 1; -i7, 41; l8, 41; 20, 31; 22, 21; 3, 21; 26, 23; 2, 1; 34, antidiabetics, 1, 164; 2, 176; 3, 156; 4, 164; 6, 192; 21, 219 antiepileptics, 33, 61 antifungal agents, 32, 151; 33, 173, 35, 157 antifungals, 2, 157; 3, 145; 3, 138; 5, 129; 6, 129; z, 109; 8, 116; 9, 107; IJ, 120; IJ, 101; l3, 113; l5, 139; ‘lJ, 139; IQ, 127; 22, 159; 24, 111; 25, 141; 27, 149 antiglaucoma agents, 20, 83 anti-HCV therapeutics, 34, 129 antihyperlipidemics, l5, 162; l8, 161; 24, 147 antihypertensives, 1, 59; 2, 48; 3, 53; 4, 47; 5, 49; 6, 52; 7, 59; 8, 52; 9, 57; 11, 61; IZ, 60; l3, 71; VI, 61; l5, 79; l6, 73; l7, 61; l8, 69; l9, 61; 2J, 63; 2, 63; 23, 59; 24, 51; 25, 51 antiinfective agents, 28, 119 antiinflammatory agents, 28, 109; 29, 103 antiinflammatories, non-steroidal, ?_, 224; 2, 217; 3, 215; 4, 207; 5, 225; 6, 182; 7,208;& 214;!j, 193;lO, 172; IJ, 167;E, 189;23, 181 anti-ischemic agents, l7, 71 antimalarial inhibitors, 3, 159 antimetabolite concept, drug design, 11, 223 antimicrobial drugs - clinical problems and opportunities, 21, 119
Cumulative
Chapter
Tiles
Keyword
Index,
Vol.
l-36
antimicrobial potentiation, 33, 121 antimicrobial peptides, 27, 159 antimitotic agents, 34, 139 antimycobacterial agents, 3J, 161 antineoplastics, 2, 166; 3, 150; 4, 154; 5, 144; 1, 129; 8, 128; 9, 139; l0, 131; VI, 110; l2, 120; l3, 120; l4, 132; l5, 130; l6, 137; IJ, 163; I& 129; IJ, 137; 20, 163; 22, 137; 24, 121; 28, 167 antiparasitics, 1, 136, 150; 2, 131, 147; 3, 126, 140; 4, 126; 5, 116; 1, 145; 6, 141; 9, 115; lo, 154; 11, 121; l2, 140; l3, 130; 14, 122; l5, 120; I& 125; l7, 129; l9, 147; 26, 161 antiparkinsonism drugs, 6, 42; 9, 19 antiplatelet therapies, 35, 103 antipsychotics, 1, 1; 2, 1; 3, 1; 4, 1; 5, 1; 6, 1; 1, 6; 8, 1; 9, 1: IO, 2; lJ, 3; 2, 1; l3,11;l4,12;15,12;l& 11;~,21;19,21;2l, 1;22,1;23,1;24,1;~, l;B, 53; 27,49; 2a, 39; 33,l antiradiation agents, ‘l, 324; 2, 330; 3, 327; 5, 346 anti-retroviral chemotherapy, 25, 149 antiretroviral drug therapy, 32, 131 antiretroviral therapies, 35, 177; 36, 129 antirheumatic drugs, l6, 171 antisense oligonucleotides, 23, 295; 33, 313 antisense technology, 29, 297 antithrombotics, 7, 78; 8, 73; 9, 75; l0, 99; l2, 80; 14, 71; l7, 79; 27, 99; 32, 71 antithrombotic agents, 29, 103 antitumor agents, 3, 121 antitussive therapy, S, 31 antiviral agents, ?_, 129; 2, 122; 3, 116; 4, 117; 5, 101; 5, 118; 7, 119; 6, 150; 9, 128; IO, 161; IJ, 128; l3, 139; l5, 149; 16, 149; 18, 139; 19, 117; 22, 147; 23, 161; 24, 129; 26, 133; 28, 131; 29, 145; 30, 139; 2, 141; 33, 163 antitussive therapy, 35, 53 anxiolytics, 26, 1 apoptosis, 31, 249 aporphine chemistry, 4, 331 arachidonate lipoxygenase, 16, 213 arachidonic acid cascade, l2, 182; 14, 178 arachidonic acid metabolites, IJ, 203; 23, 181; 3, 71 arthritis, l3, 167; l6, 189; l7, 175; l8, 171; 2J, 201; 23, 171, 181; 3,203 arthritis, immunotherapy, 23, 171 aspartyl proteases, x, 247 asthma, 29, 73; 32, 91 asymmetric synthesis, IJ, 282 atherosclerosis, 1, 178; 2, 187; 3, 172; 4, 178; 5, 180; 6, 150; I, 169; 8, 183; 15, 162; l8, 161; 21, 189; 3, 147; 25, 169; 28, 217; 2, 101; 3, 101; 36, 57 atherothrombogenesis, 31, 101 atrial natriuretic factor, 21, 273; 23, 101 autoimmune diseases, 34, 257 autoreceptors, 19, 51 bacterial adhesins, 2L3, 239
353 -
-354
Cumuiatlve
Chapter
Titles
Keyword
Index,
Vol. 1-36
bacterial genomics, 32, 121 bacterial resistance, lJ, 239; 17, I 19; 32, I I I bacterial toxins, l2, 211 bacterial virulence, 30, 111 basophil degranulation, biochemistry, lJ, 247 Bcl2 family, 3l, 249; 33, 253 behavior, serotonin, 7, 47 benzodiazepine receptors, l6, 21 bioinformatics, 36, 201 bioisosterism, 2l, 283 biological factors, IO, 39; II, 42 biological membranes, 11, 222 biopharmaceutics, 1, 331; 2, 340; 3, 337; 4, 302; 5, 313; 6, 264; 7, 259; & 332 biosensor, 30,275 biosynthesis, antibotics, l2, 130 biotechnology, drug discovery, 25, 289 blood-brain barrier, 3, 305 blood enzymes, 1,233 bone, metabolic disease, l2, 223; l5, 228; lJ, 261; 22, 169 bone metabolism, 26, 201 brain, decade of, 27, 1 calcium antagonists/modulators, l6, 257; l7, 71; 18, 79; 2_1, 85 calcium channels, 30, 51 calmodulin antagonists, SAR, I& 203 cancer, 27, 169; 31,241; 34, 121; 35, 123; 3, 167 cancer chemotherapy, 29, 165 cancer cytotoxics, 33, 151 cancer, drug resistance, 23, 265 cancer therapy, 2, 166; 3, 150; 4, 154; 5, 144; 1, 129; 8, 128; 9, 139, 151; a, 131; II, 110; l2, 120; l3, 120; l4, 132; l5, 130; l6, 137; l7, 163; l8, 129; 2l, 257; 23, 151 cannabinoid receptors, 9, 253; 34, 199 carbohydrates, 27, 301 carboxylic acid, metalated, l2, 278 carcinogenicity, chemicals, l2, 234 cardiotonic agents, l3, 92; ‘IJ, 93; l9, 71 cardiovascular, l0, 61 caspases, 33, 273 catalysis, intramolecular, 1, 279 catalytic antibodies, 25, 299; 30, 255 cell adhesion, 29, 215 cell adhesion molecules, 25, 235 cell based mechanism screens, 28, 161 cell cycle, 3l, 241; 3, 247 cell cycle kinases, 36, 139 cell invasion, l4, 229 cell metabolism, 1, 267 cell metabolism, cyclic AMP, 2, 286
Cumulative
Chapter
TEles
Keyword
Index,
355 -
Vol. 1-36
cellular responses, inflammatory, l2, 152 chemoinformatics, 33, 375 chemokines, 3,209; 35,191 chemotaxis, l5, 224; l7, 139, 253; 24, 233 cholecystokinin, l-8, 31 cholecystokinin agonists, 3, 191 cholecystokinin antagonists, 26, 191 cholesteryl ester transfer protein, 35, 251 chronopharmacology, II, 251 circadian processes, 27, 11 coagulation, 26, 93; 33, 81 cognition enhancers, 25, 21 cognitive disorders, l9, 31; 21, 31; 23, 29; 31, 11 collagenase, biochemistry, 25, 177 collagenases, 19,231 colony stimulating factor, 21, 263 combinatorial chemistry, 34, 267; 34, 287 combinatorial libraries, 3l, 309; 3l, 319 combinatorial mixtures, 32, 261 complement cascade, 27? 199 complement inhibitors, l5, 193 complement system, 7,228 conformation, nucleoside, biological activity, 5, 272 conformation, peptide, biological activity, X3, 227 conformational analysis, peptides, 23, 285 congestive heart failure, 22, 85; 35, 63 contrast media, NMR imaging, 24, 265 corticotropin-releasing factor, 25, 217; 30, 21; 34, 11 corticotropin-releasing hormone, 32, 41 cotransmitters, 20, 51 cyclic AMP, 2, 286; 6, 215; 8, 224; IJ, 291 cyclic GMP, 11, 291 cyclic nucleotides, 9, 203; 10, 192; l5, 182 cyclin-dependent kinases, 32, 171 cyclooxygenase, 30, 179 cyclooxygenase-2 inhibitors, 32, 211 cysteine proteases, 35, 309 cystic fibrosis, 27, 235; 36, 67 cytochrome P-450,9, 290; l9, 201; 32, 295 cytokines, 27, 209; 31, 269; 34, 219 cytokine receptors, 26, 221 database searching, 3D, 28,275 DDT-type insecticides, 9, 300 dermal wound healing, 24, 223 dermatology and dermatological agents, 12, 162; 18, 181; 2, 201; 3, 177 designer enzymes, 25, 299 diabetes, 9, 182; 11, 170; l3, 159; 19, 169; 22,213; 25, 205; 2, 159; a,21 Diels-Alder reaction, intramolecular, 9, 270
3
356
Cumulatloe
Chapter
Tales
Keyword
distance geometry, 26, 281 diuretic, 1, 67; 2, 59; 3, 62; S, 88; 8, 83; 10, 71; II, DNA binding, sequence-specific, 21, 311; 22, 259 DNA vaccines, 34, 149 docking strategies, 26, 275 dopamine,l3,11;H,12;15,12;~,11,103;~,21;~,41;~,107 dopamine D3,29,43 dopamine D4,29,43
Index,
Vol. 136
71; 13, 61; 15, 100
DPP-IV Inhibition, 3, 191 drug abuse, CNS agents, 9, 38 drug allergy, 3, 240 drug carriers, antibodies, l5, 233 drug carriers, liposomes, 14, 250 drug delivery systems, 15, 302; 18, 275; 20, 305 drug design, 34, 339 drug design, computational, 33, 397 drug design, metabolic aspects, 23, 315 drug discovery, l7, 301; 34, ; 34, 307 drug disposition, l5, 277 drug metabolism, 3, 227; 4, 259; 5, 246; f3, 205; 8, 234; 9, 290; IJ, 190; 12, 201 l3, 196, 304; 14, 188; l6, 319; l7, 333; 23, 265, 315; 29, 307 drug receptors, 25, 281 drug resistance, 23, 265 EDRF, 27,69 elderly, drug action, 20, 295 electrospray mass spectrometry, 32, 269 electrosynthesis, IJ, 309 enantioselectivity, drug metabolism, l3, 304 endorphins, IJ, 41; l4, 31; 15, 32; s,41; IJ, 21; IJ, 51 endothelin, 3l, 81; 32, 61 endothelin antagonism, 35, 73 endothelin antagonists, 29, 65, 30, 91 enzymatic monooxygenation reactions, l5, 207 enzyme inhibitors, 1, 249; 9, 234; l3, 249 enzyme immunoassay, 18,285 enzymes, anticancer drug resistance, 23, 265 enzymes, blood, 1, 233 enzymes, proteolytic inhibition, l3, 261 enzyme structure-function, 22, 293 enzymic synthesis, 19, 263; 23, 305 epitopes for antibodies, 2JI 189 erectile dysfunction, 3, 71 estrogen receptor, 31, 181 ethnobotany, 29, 325 excitatory amino acids, 22, 31; 24, 41; 3, 11; 29, 53 ex-vivo approaches, 35, 299 factor Xa, 3, 51; 34, 81 factor Xa inhibitors, 35, 83
Cumulative
Chapter Titles Keyword
Index, Vol. l-36
fertility control, IJ, 240; l4, 168; 21, 169 filiarial nematodes, 35, 281 forskolin, l9, 293 free radical pathology, a, 257; 22, 253 fungal resistance, 35, 157 G-proteins, 23, 235 GABA, antagonists, l3, 31; 15, 41 galanin receptors, 33, 41 gamete biology, fertility control, l0, 240 gastrointestinal agents, 1, 99; 2, 91; 4, 56; 6> 68; 8, 93; 10. 90; 12, 91; 16, 83; l7,89; 1_8,89; a,1 17; 23,201 gender based medicine, 33, 355 gene expression, 32, 231 gene expression, inhibitors, 23, 295 gene targeting technology, 29, 265 gene therapy, 8, 245; 30, 219 genetically modified crops, 3, 357 gene transcription, regulation of, 27, 311 genomics, 34, 227 glucagon, 34, 189 glucagon, mechanism, l8, 193 f&D-glucans, 3, 129 glucocorticosteroids, IJ, 179 glutamate, 31, 31 glycoconjugate vaccines, 28, 257 glycopeptide antibiotics, 3l, 131 glycoprotein Ilb/llla antagonists, 28, 79 glycosylation, non-enzymatic, 14, 261 gonadal steroid receptors, 3, 11 gonadotropin releasing hormone, 0, 169 GPllb/llla, 31, 91 G protein-coupled receptors, 35, 271 growth factor receptor kinases, 3Ji, 109 growth factors, 21, 159; 24, 223; 28, 89 growth hormone, 20, 185 growth hormone secretagogues, 28, 177; 32, 221 guanylyl cyclase, 27, 245 hallucinogens, 1, 12; 2, 11; 3, 14; 4, 13; 5, 23; 6, 24 HDL cholesterol, 35, 251 heart disease, ischemic, l5, 89; l7, 71 heart failure, l3, 92; l6, 93; 22, 85 helicobacter pylori, 30, 151 hemoglobinases, 34, 159 hemorheologic agents, IJ, 99 herbicides, 17, 311 heterocyclic chemistry, 14, 278 high throughput screening, 33, 293 histamine HJ receptor agents, 33, 31
357 -
358 -
Cumulative
Chapter
Titles
Keyword
Index.
Vol. 1-36
HIV co-receptors, 33, 263 HIV protease inhibitors, S, 141; 29, 123 HIV reverse transcriptase inhibitors, 3, 123 HIV vaccine, 27, 255 homeobox genes 27,227 hormones, glycoprotein, l2, 211 hormones, non-steroidal, 1, 191; 3, 184 hormones, peptide, 5, 210; 1, 194; 6, 204; lJ, 202; II, 158; l6, 199 hormones, steroid, 1, 213; 2, 208; 3, 207; 3, 199 host modulation, infection, 8, 160; 14, 146; 18, 149 human gene therapy, 26, 315; 3,267 human retrovirus regulatory proteins, S, 171 !Shydroxytryptamine, 2, 273; 1, 47; 21, 41 hypercholesterolemia, 24, 147 hypersensitivity, delayed, 8, 284 hypersensitivity, immediate, 1, 238; 8, 273 hypertension, 2%, 69 hypertension, etiology, 9, 50 hypnotics, 1, 30; 2, 24; 3, 2%; 4, 28; z, 39; & 29; IJ, 30; II, 13; l2, ~,22;~,22,~;31;~,11;~,11;~,11;~,11 ICE gene family, 31,249 IgE, I& 247 immune mediated idiosyncratic drug hypersensitivity, 26, 181 immune system, 3,281 immunity, cellular mediated, l7, 191; I%, 265 immunoassay, enzyme, I%, 285 immunomodulatory proteins, 35, 281 immunophilins, 2%, 207 immunostimulants, arthritis, IJ, 13%; l4, 146 immunosuppressants, 26,211; 2, 175 immunosuppressive drug action, 28, 207 immunosuppressives, arthritis, IJ, 13% immunotherapy, cancer, 9, 151; 23, 151 immunotherapy, infectious diseases, I& 149; 22, 127 immunotherapy, inflammation, 23, 171 infections, sexually transmitted, l4, 114 inflammation, 22, 245; 3J, 279 inflammation, immunomodulatory approaches, 23, 171 inflammation, proteinases in, 2%, 187 inflammatory bowel disease, 3, 167 inhibitors, complement, 15, 193 inhibitors, connective tissue, l7, 175 inhibitors, enzyme, l3, 249 inhibitors, irreversible, 9, 234; l6, 289 inhibitors, platelet aggregation, 6, 60 inhibitors, proteolytic enzyme, IJ, 261 inhibitors, renin-angiotensin, 13, 82 inhibitors, reverse transcription, 8, 251
10; l3, 21
Cumulative
Chapter
Tkles
Keyword
Index.
Vol. 1-36
inhibitors, transition state analogs, z, 249 inorganic chemistry, medicinal, 8, 294 inosine monophosphate dehydrogenase, 35,201 inositol triphosphate receptors, 27, 261 insecticides, 9, 300; 17, 3 11 insulin, mechanism, l6, 193 integrins, 3, 191 62 -integrin Antagonist, S, 181 integrin alpha 4 beta 1 (VLAd), 34, 179 intellectual property, 36, 331 interferon, 8, 150; l2, 211; Is, 229; l7, 151 interleukin-1 , 20, 172; 22, 235; 3, 185; 29, 205, 33, 183 interleukin-2, l9, 191 interoceptive discriminative stimuli, animal model of anxiety, 15, 51 intramolecular catalysis, 7, 279 ion channels, ligand gated, 25, 225 ion channels, voltage-gated, 25, 225 ionophores, monocarboxylic acid, IO, 246 iron chelation therapy, l3, 219 irreversible ligands, 25, 271 ischemialreperfusion, CNS, 27, 31 ischemic injury, CNS, 25, 31 isotopes, stable, l2, 319; l9, 173 JAKs, 2,269 l3-lactam antibiotics, 11, 271; l2, 101; l3, 149; 20, 127, 137; 23, 121; 24, 101 &lactamases, l3, 239; l7, 119 ketolide antibacterials, 35, 145 LDL cholesterol, 35, 251 learning, 3, 279; 16, 51 leptin, 2, 21 leukocyte elastase inhibitors, 3, 195 leukocyte motility, l7, 181 leukotriene modulators, 32, 91 leukotrienes, l7, 291; l9, 241; 3, 71 LHRH, 20,203; 23,211 lipid metabolism, 9, 172; 10, 182; 11, 180; l2, 191; 13, 184; 14, 198; l5, 162 lipoproteins, 3, 169 liposomes, l4, 250 lipoxygenase, I& 213; 17,203 lymphocytes, delayed hypersensitivity, 8, 284 macrocyclic immunomodulators, 25, 195 macrolide antibacterials, 35, 145 macrolide antibiotics, 25, 119 macrophage migration inhibitor factor, 33, 243 magnetic resonance, drug binding, II, 311 malaria, 3l, 141; 34, 349 male contraception, 32, 191 managed care, 30,339
359 -
-360
Cumulative
Chapter
Titles
Keyword
Index,
Vol. 1-36
MAP kinase, 3l, 289 market introductions, l9, 313; 20, 315; 21, 323; 22, 315; 23, 325; 3, 295; 25, 30% 26,297; 223 321; 28,325; 29,331; 30,295; 31, 337; 2,305; 3, 327 mass spectrometry, 3l, 319; 34, 307 mass spectrometiy, of peptides, 24, 253 mass spectrometry, tandem, 2l, 213; 21, 313 mast cell degranulation, biochemistry, I& 247 matrix metailoproteinase inhibitors, 35, 167 mechanism based, anticancer agents, 25, 129 mechanism, drug allergy, 3, 240 mechanisms of antibiotic resistance, 1, 217; l3, 239; l7, 119 medicinal chemistry, 26, 34330, 329; 33, 385; 3,267 melatonin, 2, 31 membrane function, 10, 317 membrane regulators, II, 210 membranes, active transport, II, 222 memory, 3, 279; l2, 30; %,51 metabolism, cell, 1, 267; 2, 286 metabolism, drug, 3, 227; 4, 259; 5, 246; 6, 205; f3, 234; 9, 290; 11, 190; l2, 201; l3, 196,304; 14, 188; 23, 265, 315 metabolism, lipid, 9, 172; IO, 182; II, 180; 12, 191; l4, 198 metabolism, mineral, l2, 223 metabotropic glutamate receptor, 35, 1 metal carbonyls, 8, 322 metalloproteinases, 31, 231; 33, 131 metals, disease, l4, 321 metastasis, 26, 151 microbial products screening, 21, 149 migraine, 22, 41; 32, 1 mitogenic factors, 2J 237 modified serum lipoproteins, 25, 169 molecular diversity, 26, 259, 271; 2& 315; 34, 287 molecular modeling, 2, 269; 23, 285 monoclonal antibodies, l6, 243; 27, 179; 29, 317 monoclonal antibody cancer therapies, 3, 237 monoxygenases, cytochrome P-450,9, 290 multivalent ligand design, 35, 321 muscarinic agonists/antagonists, 23, 81; 3, 31; 29, 23 muscle relaxants, 1, 30; 2, 24; 3, 28; 3, 28; 8, 37 muscular disorders, IJ, 260 mutagenicity, mutagens, l2, 234 mutagenesis, SAR of proteins, 18, 237 myocardial ischemia, acute, 25, 71 narcotic antagonists, 7, 31; 8, 20; 9, 11; IJ, 12; IJ, 23; IJ, 41 natriuretic agents, l9, 253 natural products, 5, 274; 15, 255; l7, 301; 26, 259; 32, 285 natural killer cells, l8, 265 neoplasia, 8, 160; IJ, 142
Cumulative
Chapter
Titles
Keyword
Index,
Vol. 1-36
neurodegeneration, 30, 31 neurodegenerative disease, 28, 11 neurokinin antagonists, 26, 43; 31 111; 32, 51; 33, 71; 34, 51 neurological disorders, 31, 11 neuronal calcium channels, 3, 33 neuronal cell death, 29, 13 neuropeptides, 21, 51; 22, 51 neuropeptide Y, 3J, 1; 32, 21; 34, 31 neuroprotection, 29, 13 neurotensin, l7, 31 neurotransmitters, 3, 264; 4, 270; l2, 249; l4, 42; IJ, 303 neutrophic factors, 26, 245; 28, 11 neutrophil chemotaxis, 24, 233 nicotinic acetylcholine receptor, 22, 281; 35, 41 nitric oxide synthase, 29, 83; 31, 221 NMR, 27,271 NMR in biological systems, 20, 267 NMR imaging, 20,277; 2fl, 265 NMR methods, 31, 299 NMR, protein structure determination, 23, 275 non-enzymatic glycosylation, 14, 261 non-HIV antiviral agents, 36, 119 non-nutritive, sweeteners, l7, 323 nonpeptide agonists, 32, 277 non-steroidal antiinflammatories, 1, 224; 2, 217; 3, 215; 4, 207; 5, 225; 6, 182; 7, 208; 6,214; 9, 193; IO, 172; 13, 167; ‘l6, 189 novel analgesics, 35, 21 nuclear orphan receptors, 32, 251 nucleic acid-drug interactions, ‘lJ, 316 nucleic acid, sequencing, l6, 299 nucleic acid, synthesis, 16, 299 nucleoside conformation, 5, 272 nucleosides, 1, 299; 2, 304; 3, 297; 5, 333 nucleotide metabolism, 21, 247 nucleotides, 1, 299; 2, 304; 3, 297; 5, 333 nucleotides, cyclic, 9, 203; IO, 192; 15, 182 obesity, 1, 51; 2, 44; 3, 47; 5, 40; 8, 42; IJ, 200; l5, 172; 19, 157; 23, 191; 31, 201; 32,21 oligomerisation, 35, 271 oligonucleotides, inhibitors, 23, 295 oncogenes, 18,225; 21, 159,237 opioid receptor, IJ, 33; l2, 20; l3, 41; l4, 31; l5, 32; l6, 41; u, 21; l& 51; 20, 21; 2l, 21 opioids, 2, 20; l6,41; IJ, 21; 18, 51; 3, 21; 21, 21 opportunistic infections, 29, 155 oral pharmacokinetics, 35, 299 organocopper reagents, IJ, 327 osteoarthritis, 22, 179
361 -
-362
Cumulative
Chapter
Titles
Keyword
Index,
Vol. l-36
osteoporosis, 22, 169; 26, 201; 3, 275; 3l, 211 oxazolidinone antibacterials, 35, 135 P-glycoprotein, multidrug transporter, 25, 253 parallel synthesis, 3, 267 parasite biochemistry, &3, 269 parasitic infection, 36, 99 patents in medicinal chemistry, 22, 331 pathophysiology, plasma membrane, 10, 213 PDE IV inhibitors, 2, 71 penicillin binding proteins, 18, 7 19 Peptic Ulcer, 1, 99; 2, 91; 4, 56; 6, 68; ~3, 93; l0, 90; 12, 91; l6, 83; l7, 89; I& 89; l9, 81; 20,93; 22, 191; 25, 159 peptide-l , 34, 189 peptide conformation, l3, 227; 23, 285 peptide hormones, 5, 210; 7, 194; 8,204; IJ, 202; IJ, 158,l9, 303 peptide hypothalamus, 1, 194; 8, 204; 10, 202; l-6, 199 peptide libraries, 26, 271 peptide receptors, 25, 281; 32, 277 peptide, SAR, 5, 266 peptide stability, 26, 285 peptide synthesis, 5, 307; z, 289; l6, 309 peptide synthetic, 1, 289; 2, 296 peptide thyrotropin, l7, 31 peptidomimetics, 24, 243 periodontal disease, l0, 228 PET, 24,277 PET ligands, 36, 267 pharmaceutics, ‘l, 331; 2, 340; 3, 337; 4, 302; 5, 313; 5, 254, 264; 1, 259; 6, 332 pharmaceutical proteins, &I, 237 pharmacogenetics, 2,261 pharmacogenomics, 34, 339 pharmacokinetics, 5, 227, 337; 4, 259, 302; 5, 246, 313; 6, 205; 8, 234; 9, 290; IJ, 190; 12,201; l3, 196,304; l4, 188,309; 16,319; II, 333 pharmacophore identification, 15, 267 pharmacophoric pattern searching, 14, 299 phosphodiesterase, 31, 61 phosphodiesterase 4 inhibitors, 29, 185; 33, 91; 36, 41 phospholipases, 19,213; 22,223; 24, 157 physicochemical parameters, drug design, 3, 348; 4, 314; 2, 285 pituitary hormones, 7, 194; 8, 204; l0, 202 plants, 34, 237 plasma membrane pathophysiology, IO, 213 plasma protein binding, 31, 327 plasminogen activator, 18, 257; 20, 107; 23, 111; 34, 121 plasmon resonance, 33,301 platelet activating factor (PAF), l7, 243; 20, 193; 24, 81 platelet aggregation, 6, 60 polyether antibiotics, IO, 246
Cumulative
Chapter
Titles
Keyword
Index.
Vol
1-36
polyamine metabolism, l7, 253 polyamine spider toxins, 24, 287 polymeric reagents, II, 281 positron emission tomography, 24, 277, 25, 261 potassium channel activators, 3, 73 potassium channel antagonists, 27, 89 potassium channel blockers, 32, 181 potassium channel openers, 24, 91,=, 81 potassium channel modulators, 36, 11 privileged structures, 35, 289 prodrugs, 10, 306; 22, 303 profiling of compound libraries, 36, 277 programmed cell death, 3, 239 prolactin secretion, l5, 202 prostacyclin, 14, 178 prostaglandins, 3, 290; 5, 170; 6, 137; 7, 157; 8, 172; 9, 162; IJ, 80 prostanoid receptors, 33, 223 prostatic disease, 24, 197 proteases, 26, 151 proteasome, 3l, 279 protein C, 29, 103 protein growth factors, l7, 219 proteinases, arthritis, l4, 219 protein kinases, l8, 213; 29, 255 protein kinase C, 20, 227; 23, 243 protein phosphatases, 29, 255 protein structure determination, NMR, 23, 275 protein structure prediction, 36, 211 protein structure project, 31, 357 protein tyrosine kinases, 27, 169 protein tyrosine phosphatase, 35, 231 proteomics, 36, 227 psoriasis, l2, 162; 32, 201 psychiatric disorders, 11, 42 psychoses, biological factors, IO, 39 psychotomimetic agents, 9, 27 pulmonary agents, 1, 92; 2, 83; 3, 84; 4, 67; 5, 55; z, 89; 9, 85; I& 80; II, 51; IZ, 70; l3, 51; l4, 51; l5, 59; IJ, 51; l& 61; 2J. 71; 21, 73; 22, 73; 23, 69; 24, 61; 25, 61; 26, 113; 27, 109 pulmonary disease, 34, 111 pulmonary inflammation, 3J, 71 purinoceptors, 3l, 21 quantitative SAR, 5, 245; 8, 313; 11, 301; IJ, 292; 17, 281 quinolone antibacterials, 2_1, 139; 22, 117; 3, 133 radioimmunoassays, IO, 284 radioisotope labeled drugs, 7* 296 radioimaging agents, l8, 293 radioligand binding, l9, 283
363 -
364 -
Cumulative
Chapter
Txles
Keyword
Index,
Vol. 1-36
radiosensitizers, 2& 151 ras farnesyltransferase, 1, 171 ras GTPase, 3,249 ras oncogene, 29, 165 receptor binding, 12, 249 receptor mapping, 14, 299; 15, 267; 23, 285 receptor modeling, 2, 281 receptor, concept and function, 2J, 211 receptors, acetylcholine, 30, 41 receptors, adaptive changes, l9, 241 receptors, adenosine, 28, 295; 33, 111 receptors, adrenergic, l5, 217 receptors, f3-adrenergic blockers, 14, 81 receptors, benzodiazepine, l6, 21 receptors, cell surface, l2, 211 receptors, drug, 1, 236; 2, 227; 8, 262 receptors, G-protein coupled, 23, 221, 27, 291, receptors, G-protein coupled CNS, 28, 29 receptors, histamine, 14, 91 receptors, muscarinic, 24, 31 receptors, neuropeptide, 28? 59 receptors, neuronal BZD, 28, 19 receptors, neurotransmitters, 3, 264; l2, 249 receptors, neuroleptic, 12, 249 receptors, opioid, ll, 33; l2, 20; l3, 41; l4, 31; 15, 32; Is, 41; l7, 21 receptors, peptide, 25, 281 receptors, serotonin, 23, 49 receptors, sigma, 28, 1 recombinant DNA, 17,229; l8, 307; 19,223 recombinant therapeutic proteins, 3, 213 renal blood flow, 16, 103 renin, l3, 82; 20, 257 reperfusion injury, 22, 253 reproduction, 1, 205; 2, 199; 3, 200; 4, 189 resistant organisms, 34, 169 retinoids, 3, 119 reverse transcription, 8, 251 RGD-containing proteins, 28, 227 rheumatoid arthritis, II, 138; l4, 219; l8, 171; 21, 201; 23, 171, 181 ribozymes, 30,285 SAR, quantitative, 5, 245; 8, 313; IJ, 301; l3, 292; lJ, 291 same brain, new decade, 36, 1 secretase inhibitors, 35, 31; sedative-hypnotics, 7, 39; 8, 29; lJ, 13; lJ, 10; l3, 21; VJ, 22; l5, 22; 16, 31; u ll;B, 11,l9,11;2J, 11 sedatives, 1, 30; 2, 24; 3, 28; 4, 28; 7, 39; 8, 29; lJ, 30; lJ, 13; lJ, 10; l3, 21 ~,22;~;22;~,31;~, ll;B, 11;2CJ, 1;2J, 11 sequence-defined oligonucleotides, 26, 287
Cumulative
Chapter
Tnles
Keyword
Index,
Vol. l-36
serine proteases, 32, 71 SERMs, 36, 149 serotonergics, central, 25, 41; 27, 21 serotonin, 2, 273; 1, 47; 26, 103; 3, 1; 33, 21 serotonin receptor, 35, 11 serum lipoproteins, regulation, lJ, 184 sexually-transmitted infections, 14, 114 SH2 domains, 0,227 SH3 domains, 3,227 silicon, in biology and medicine, 10, 265 sickle cell anemia, 20, 247 signal transduction pathways, 33, 233 skeletal muscle relaxants, 6, 37 sleep, 27, 11; 34, 41 slow-reacting substances, ‘l5, 69; l6, 213; l7, 203, 291 sodium/calcium exchange, 20, 215 sodium channels, 33, 51 solid-phase synthesis, 31, 309 solid state organic chemistry, 20, 287 solute active transport, lJ, 222 somatostatin, l4, 209; l8, 199; 3, 209 spider toxins, 3, 287 SRS, l5,69; l6, 213; l7, 203, 291 STATS,, 269 stereochemistry, 25, 323 steroid hormones, 1, 213; 2, 208; 3, 207; 4, 199 stroidogenesis, adrenal, 2, 263 steroids, 2, 312; 3, 307; 3, 281; 5, 192, 296; 6, 162; 1, 182; 6, 194; ‘lJ, 192 stimulants, 1, 12; 2, 11; 3, 14; 4, 13; 5, 13; 6, 15; 1, 18; 8, 11 stroke, pharmacological approaches, 2J, 108 stromelysin, biochemistry, 25, 177 structure-based drug design, 27, 271; 30, 265; 3, 297 substance P, l7, 271; l8, 31 substituent constants, 2, 347 suicide enzyme inhibitors, 16, 289 superoxide dismutases, 10, 257 superoxide radical, l0, 257 sweeteners, non-nutritive, l7, 323 synthesis, asymmetric, lJ, 282 synthesis, computer-assisted, 2, 288; I& 281; 21, 203 synthesis, enzymic, 23, 305 T-cells, 27, 189; 33, 199; 34, 219 tachykinins, 28, 99 taxol, 28, 305 technology, providers and integrators, 3, 365 thalidomide, 30, 319 therapeutic antibodies, 36, 237 thrombin, 30, 71, 31, 51; 34, 81
365
366 -
Cumulative
Chapter
Titles
Keyword
thrombolytic agents, 29, 93 thrombosis, 5, 237; S, 93; 33, 81 thromboxane receptor antagonists, 25, 99 thromboxane synthase inhibitors, 25, 99 thromboxane synthetase, 22, 95 thromboxanes, l4, 178 thyrotropin releasing hormone, l7, 31 TNF-cx, 32, 241 topoisomerase, 2J, 247 toxicity reversal, 15, 233 toxicity, mathematical models, 18, 303 toxicology, comparative, ll, 242; 33, 283 toxins, bacterial, l2, 211 transcription factor NF-~8, 29, 235 transcription, reverse, 8, 251 transgenic animals, 24, 207 transgenic technology, 29, 265 translational control, 29, 245 traumatic injury, CNS, 25, 31 trophic factors, CNS, 27, 41 tumor necrosis factor, 22, 235 type 2 diabetes, 35, 211 tyrosine kinase, 30, 247; 31, 151 urokinase-type plasminogen activator, 34, 121 vascular proliferative diseases, 30, 61 vasoactive peptides, 25, 89; 3, 83; 27, 79 vasoconstrictors, 3, 77 vasodilators, 4, 77; l2, 49 vasopressin antagonists, 23, 91 vasopressin receptor modulators, 36, 159 veterinary drugs, l6, 161 viruses, l4, 238 vitamin D, lO,295; 15,288; l7, 261; l9, 179 waking functions, l0, 21 water, structures, 5, 256 wound healing, 24, 223 xenobiotics, cyclic nucleotide metabolism, I& 182 xenobiotic metabolism, 23, 315 x-ray crystallography, 2l, 293; 27, 271
Index,
Vol. 1-36